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Abstract 
Objective: To investigate predictors of hepatic steatosis in HBeAg-negative chronic hepatitis 
B (CHB) patients and their diagnostic values in hepatic inflammation and fibrosis. Methods: A 
total of 106 HBeAg-negative CHB patients with clinically and pathologically proven steatosis 
and 98 patients without steatosis were recruited into this study. The levels of fasting blood 
glucose (FBG), fasting insulin (FINS), triglyceride (TG), cholesterol (CHOL), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), albumin (Alb), globulin (Glb), HBV 
DNA, body mass index (BMI), homeostatic model assessment of insulin resistance 
(HOMA-IR) and pathological changes of the liver in inflammation, fibrosis and fatty deposition 
were examined in all patients. Results: The levels of BMI, HOMA-IR, FBG, insulin, TG, and 
CHOL were significantly higher in patients with steatosis than those without steatosis (all 
P<0.05). But ALT, AST and HBV DNA levels were significantly lower in patients with steatosis 
(all P<0.05). Logistic regression analysis showed that only FINS was a significant predictor for 
hepatic steatosis (P<0.05); FINS and Glb were significant predictors for hepatic inflammation 
(all P<0.05); BMI and TC were significant predictors for hepatic fibrosis (all P<0.05). Con-
clusions: Hepatic steatosis, a common disease in HBeAg-negative CHB patients, was posi-
tively associated with BMI, FBG, FINS, TG, TC, GGT, ALP and HOMA-IR. In these patients, 
the prevalence of hepatic inflammation and fibrosis was also increased. 
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Introduction 
The prevalence of HBeAg-negative chronic he-
patitis B (CHB) tends to increase in recent years (1). 
With the improvement of living standard and nutri-
tion status, hepatic steatosis frequently occurs in CHB 
patients. It has been shown that the incidence of he-
patic steatosis in CHB patients was about 32% (2). The 
distribution of hepatic triglyceride content (HTGC) in 
2, 287 subjects from a multiethnic, population-based 
sample (32.1% white, 48.3% black, and 17.5% His-
panic) was previously examined and compared using 
proton magnetic resonance spectroscopy. Almost one 
third of the population had hepatic steatosis, and 
most subjects with hepatic steatosis had normal levels 
of serum alanine aminotransferase (ALT). The higher 
prevalence of hepatic steatosis in Hispanics was 
mainly due to the higher prevalence of obesity and 
insulin resistance in this ethnic group (3). But, that 
how does hepatic steatosis influence CHB still re-
mains unclear (4), particularly in HBeAg-negative 
CHB patients. In contrast, a large body of evidence 
showed the incidence of hepatic steatosis in chronic 
hepatitis C (CHC) patients ranged from 31% to 72%. 
Moreover, it has been suggested that hepatic steatosis 
in CHC has correlations with obesity, disorder of fat Int. J. Med. Sci. 2010, 7 
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metabolism, insulin resistance and HCV genotypes 
(5). This study analyzed and compared the clinical 
and histological features of HBeAg-negative CHB 
patients with or without hepatic steatosis, so as to 
evaluate the predictors of clinical and pathological 
characteristics in these patients with steatosis and 
their diagnostic values in hepatic fibrosis.  
Patients and methods 
Patients  
A total of 204 HBeAg-negative CHB patients 
were recruited from the Research and Therapy Center 
for Liver Diseases of China Southeast Hospital from 
May 2005 to March 2009. Most patients did not drink 
alcohol, and alcohol consumption in the remaining 
patients was less than 20g/day. These patients were 
divided in two groups according to presence of he-
patic steatosis. Among all HBeAg-negative CHB par-
ticipants, 106 were diagnosed as hepatic steatosis (83 
men and 23 women, mean age: 41.08±10.23 years) and 
the remaining 98 patients were excluded from hepatic 
steatosis (79 men and 19 women, mean age 39.4±9.81 
years). Their diagnoses were finally confirmed by 
clinical presentations and pathological features. The 
criteria for hepatic steatosis were based on the Amer-
ican Association for the Study of Liver Diseases Prac-
tice Guidelines (2007) (6). Hepatitis A virus (HAV), 
HCV, Hepatitis D virus (HDV) and Hepatitis E virus 
(HEV) infection, drug-induced hepatitis, alcoholic 
hepatitis and autoimmune hepatitis were all ex-
cluded. Clinical data were obtained and recorded 
immediately after enrollment.  
Body mass index (BMI)  
BMI was calculated as the individual's body 
weight divided by the square of his or her height. 
According to the new BMI criteria for Asians by the 
regional office for the western pacific region of WHO 
(WHO Technical Report Series No. 894, WHO, Gene-
va, 2000), normal weight, overweight, Obese Class I 
and Obese Class II were defined by BMI= 18.5-22.9 
kg/m2, 23.0-24.9 kg/m2, 25.0-29.9kg/m2 and ≥30 
kg/m2, respectively.  
Serum markers of HBV  
HBV markers, including HBsAg, anti-HBs, an-
ti-HBc, HBeAg and anti-HBe were measured by en-
zyme-linked immunosorbent assay (Livzon Group 
Reagent Factory, Guangdong, China). 
HBV DNA 
The HBV DNA level was determined by quan-
titative polymerase chain reaction (qPCR) (AcuGen 
HBV quantitative test; Biotronic Corp., Lowell, Mass.) 
with the fluorescent HBV DNA probes provided by 
the same company. Asymmetric primer 1 was 
5′-TGTCTCGTGTTACAGGCGGGGT-3', asymmetric 
primer 2 was 5′-GAGGCATAGCAGCAGGA 
GAAGAG-3', and fluorescent primer was 
5′-TCGCTGGAAGTGTCTGCGGCGT-3'.  
Serum assays  
Fasting blood was collected with a 
un-anticoagulated vacuum blood collection tube. Se-
rum was separated by centrifugation at 4°C and 
stored in a sterile tube at -40°C within 4 h. The levels 
of fasting blood glucose (FBG), insulin, triglyceride 
(TG), cholesterol (CHOL), ALT, aspartate amino-
transferase (AST), γ-glutamyltransferase (GGT), alka-
line phosphatases (ALP), albumin (Alb) and globulin 
(Glb) were determined.  
Homeostatic model assessment of insulin resis-
tance (HOMA-IR) 
HOMA-IR was calculated by means of the ho-
meostasis model assessment (HOMA-R) previously 
described, where HOMA-R=insulin/(22.5 e - ln glucose) 
(7).  
Histological evaluation  
All 204 specimens from liver biopsy were 1.0~2.5 
cm in length. Liver biopsy was performed to obtain 
the specimens under the guidance of ultrasound 
within 1 week after admission, using a needle with an 
internal diameter of 1.4 mm (Quick-Cut; Hakko. 
Company, Japan). Each specimen was longer than 1 
cm and had more than 6 portal areas. Specimens were 
fixed in buffered formalin, embedded in paraffin, and 
stained with hematoxylin-eosin-safran and Masson's 
trichrome. Hepatic steatosis, stage of fibrosis and 
grade of disease activity were determined according 
to the Guidelines for the assessment and management 
of non-alcoholic fatty liver disease in the Asia-Pacific 
region (8). Microvesicular steatosis was also graded 
as: F0 (<5% hepatocytes with microvesicular steato-
sis), F1 (5~30% hepatocytes involved), F2 (31~50% 
hepatocytes involved), F3 (51~75% involved) and F4 
(>75% hepatocytes involved). Fibrosis stage was de-
fined as S0 (no fibrosis), S1 (mild fibrosis), S2 (mod-
erate fibrosis), S3 (severe fibrosis), and S4 (cirrhosis), 
and grade of disease activity was defined as G0 (no 
activity), G1 (mild activity), G2 (moderate activity), 
and G3 (severe activity). All the sections were blindly 
and independently assessed by 3 pathologists and the 
results were processed by the Kappa concordance 
test. The inter- and intra-observer agreements were 
excellent.  Int. J. Med. Sci. 2010, 7 
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Statistical analysis  
Data were analyzed with the SPSS 12.0 statistical 
package (SPSS Inc., Chicago, IL, USA). Baseline cha-
racteristics and anthropometric indices were ex-
pressed as means ± standard deviation (SD) or per-
centage frequency, if necessary. The baseline charac-
teristic and anthropometric indices were compared 
between HBeAg-negative CHB patients with steatosis 
and those without steatosis by independent t test for 
continuous variables and Chi-square test for categor-
ical variables. A binary logistic regression model was 
used to determine predictors and their odds ratios for 
hepatic steastosis among HBeAg-negative CHB pa-
tients. To screen the predictors for both hepatic in-
flammation and fibrosis stages, multivariate logistic 
regression models with adjustment for age and 
gender were employed. For all comparisons, 
two-tailed P values of less than 0.05 were considered 
statistically significant.  
Results  
A total of 106 patients were diagnosed as hepatic 
steatosis (83 men and 23 women, mean age: 
41.08±10.23 years), and 98 patients excluded from 
hepatic steatosis (79 men and 19 women, mean age 
39.4±9.81 years) served as controls. There was no sig-
nificant difference in age or gender between both 
groups (P>0.05). Clinical characteristics and some 
anthropometric indices of HBeAg-negative CHB pa-
tients with or without steatosis are listed in Table 1. 
HBeAg-negative CHB patients with steatosis had sig-
nificantly higher levels of BMI, FBG, FINS, TG, TC, 
GGT, ALP, Glb and HOMA-IR (all P<0.05) than did 
those without steatosis. However, the HBV DNA, 
AST, ALT and Alb levels were significantly lower in 
patients with steatosis (all P <0.05).  
Histological features of HBeAg-negative CHB 
patients with or without steatosis were summarized 
in Table 2.  
Table 1 Clinical characteristics and anthropometric indices of HBeAg-negative CHB patients with and without steatosis  
  CHB with steatosis  CHB without steatosis  P value 
Number 106  98   
BMI (kg/m2) 28.66±1.62  20.74±1.01  0.0078 
 FBG (mmol/L) 6.79±0.84  4.37±0.26  0.0371 
FINS (U/L) 16.31±1.27  11.62±0.84  0.0013 
TG (mmol/l) 3.99±0.22  2.65±0.10  0.0064 
TC (mmol/l) 5.87±0.62  3.70±0.57  0.0216 
ALT (U/L) 110.82±21.59  366.90±86.87  0.0014 
AST (U/L) 92.61±15.38  157.62±23.31  0.0291 
GGT (U/L) 79.99±11.70  48.63±6.72  0.0116 
ALP (U/L) 157.514±14.72  83.46±14.72  0.0268 
Alb (g/L) 41.03±4.06  47.89±4.73  0.0307 
Glb (g/L) 41.84±11.73  31.22±7.49  0.0053 
HOMA-IR 5.86±1.03  3.02±0.91  0.0396 
HBV DNA (log10 copies/ml) 3.29±1.08  5.61±0.91  0.0081 
Table 2 Histological features of HBeAg-negative CHB patients with and without steatosis 
  CHB with steatosis (%)  CHB without steatosis (%)  P value 
Number 106  98   
Steatosis      
F0 0  98(100)   
F1 23(21.70) 0    
F2 25(23.58) 0    
F3 34(32.08) 0    
F4 24(22.64) 0    
Inflammation activity      
G0 17(16.04) 4 (4.08)  0.019 
G1 51(48.11) 13(13.27)  0.000 
G2 23(21.70) 47(47.96)  0.002 
G3 15(14.15) 34(34.69)  0.010 
Fibrosis stage      
S0 34(32.08) 2 (2.04)  0.000 
S1 49(46.22) 15(15.31)  0.000 
S2 11(10.38) 23(23.47)  0.046 
S3 6(5.66) 42(42.85)  0.000 
S4 6(5.66) 16(16.33)  0.054 
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The results of binary logistic regression are 
shown in Table 3. Among all indices and laboratory 
characteristics, FINS was the only characteristic that 
strongly associated with hepatic steatosis in 
HBeAg-negative CHB patients. The OR of FINS 
(every 1-unit increase) was 31.757 [95% confidence 
interval (CI) 6.899~45.454, P<0.001]. The regression 
function for predicting hepatic steatosis among 
HBeAg-negative CHB patients could be defined as 
P=e-240.827+17.165FINS/(1+ e-240.827+17.165FINS). The results of 
multivariate regression for hepatic inflammation are 
shown in Table 4. TG, GGT, Glb, and FINS were all 
associated with hepatic inflammation in each stage 
among HBeAg-negative CHB patients, but only FINS 
and Glb were strong predictors tested by likelihood 
ratio test (P=0.014, and P=0.013, respectively). Taken 
G0 stage as reference, each regression model could be 
expressed as follows: G1: 
P1=e-3.3-2.347TG-0.057GGT+0.234Glb+0.461FINS/(e-3.3-2.347TG-0.057+0.234
Glb+0.461FINS +e18.690-1.698TG-0.023GGT+0.083Glb-0.082FINS + 
e8.537-2.448TG-0.057GGT+0.034Glb+0.207FINS); G2: 
P2=e18.690-1.698TG-0.023GGT+0.083Glb-0.082FINS/(e-3.3-2.347TG-0.057+0.23
4Glb+0.461FINS +e18.690-1.698TG-0.023GGT+0.083Glb-0.082FINS + 
e8.537-2.448TG-0.057GGT+0.034Glb+0.207FINS); G3: P3= 
e8.537-2.448TG-0.057GGT+0.034Glb+0.207FINS/(e-3.3-2.347TG-0.057+0.234Glb+
0.461FINS +e18.690-1.698TG-0.023GGT+0.083Glb-0.082FINS + 
e8.537-2.448TG-0.057GGT+0.034Glb+0.207FINS); G0: 
P0=1/(e-3.3-2.347TG-0.057+0.234Glb+0.461FINS 
+e18.690-1.698TG-0.023GGT+0.083Glb-0.082FINS + 
e8.537-2.448TG-0.057GGT+0.034Glb+0.207FINS). Similarly, the results 
of multivariate regression for hepatic fibrosis were 
shown in Table 5. BMI and TC were strongly predic-
tors of hepatic fibrosis among HBeAg-negative CHB 
patients tested by likelihood ratio test (P=0.033 and 
P=0.025, respectively). Regression function for each 
stage could be expressed as follows: S1: 
P1=e-22.942+0.087BMI+4.203TC/( e-22.942+0.087BMI+4.203TC+ 
e-14.352-0.390BMI+5.146TC+ e-18.024-0.253BMI+5.224TC+ 
e-39.445+0.199BMI+6.543TC); S2: P2= e-14.352-0.390BMI+5.146TC/( 
e-22.942+0.087BMI+4.203TC+ e-14.352-0.390BMI+5.146TC+ 
e-18.024-0.253BMI+5.224TC+ e-39.445+0.199BMI+6.543TC); S3: P3= 
e-18.024-0.253BMI+5.224TC/( e-22.942+0.087BMI+4.203TC+ 
e-14.352-0.390BMI+5.146TC+ e-18.024-0.253BMI+5.224TC+ 
e-39.445+0.199BMI+6.543TC); S4: P4= e-39.445+0.199BMI+6.543TC/( 
e-22.942+0.087BMI+4.203TC+ e-14.352-0.390BMI+5.146TC+ 
e-18.024-0.253BMI+5.224TC+ e-39.445+0.199BMI+6.543TC); S0: P0=1/( 
e-22.942+0.087BMI+4.203TC+ e-14.352-0.390BMI+5.146TC+ 
e-18.024-0.253BMI+5.224TC+ e-39.445+0.199BMI+6.543TC). 
 
Table 3 Binary logistic regression analysis was performed to screen predictors for hepatic steatosis in HBeAg-negative 
CHB patients  
  B  SE  Wald χ2  P  OR  95% CI 
FINS 17.165  1432.081  19.148  1.210E-3  31.757 6.899~45.454 
Constant -240.827  20161.091  20.373  6.374E-6  0.107  
Cox and Snell R2  0.750          
Nagelkerke R2  0.830          
Overall percentage 82%           
 
 
 
Table 4 Multinomial logistic regression analysis was performed to screen predictors for hepatic inflammation grades in 
HBeAg-negative CHB patients. Categorical variables were defined as follows: G0: 0, G1: 1, G2: 2, G3: 3. 
 G  Wald χ2 P  OR  95%CI  Cox and Snell R2 Model  fitting  test 
TG 1  7.004  0.008  0.096  0.017~0.544  0.271  P=0.001 
2 2.547  0.111  0.183  0.023~1.473  0.271  P =0.001 
3 4.331  0.037  0.086  0.009~0.867  0.271  P =0.001 
GGT 1  4.330  0.037  0.945  0.896~0.997  -  - 
2 0.620  0.431  0.977  0.922~1.035  -  - 
3 3.246  0.072  0.944  0.887~1.005  -  - 
Glb 1  5.542 0.019 1.263  1.040~1.535  -  - 
2 0.570  0450  1.087  0.875~1.350  -  - 
3 0.076  0.782  1.034  0.814~1.314  -  - 
FINS 1  0.955  0.328  1.585  0.629~3.995  -  - 
2 2.681  0.102  0.435  0.161~1.178  -  - 
3 0.137  0.711  1.230  0.411~3.677  -  - 
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Table 5 Multinomial logistic regression analysis was performed to screen predictors for hepatic fibrosis stages in 
HBeAg-negative CHB patients. Categorical variables were defined as follows: S0: 0, S1: 1, S2: 2, S3: 3, S4: 4. 
S Index  Wald χ2  P  OR 95%CI Cox and Snell R2  Model P 
S1 BMI  0.019  0.890  1.090  0.320~3.717  0.170 0.011 
TC 1.796  0.180  66.911  0.143~31279.998 
S2 BMI  0.404  0.525  0.677  0.203~2.256  0.170 0.011 
TC 2.720  0.099  171.712  0.379~77702.459 
S3 BMI  0.174  0.677  0.776  0.236~2.556  0.170 0.011 
TC 2.838  0.092  185.683  0.426~80963.996 
S4 BMI  0.098  0.754  1.220  0.352~4.220  0.170 0.011 
TC 4.314  0.038  694.314  1.446~333294.121 
 
Discussion  
HBeAg-negative and HBeAg-positive hepatitis 
are two different types of chronic hepatitis B with 
distinct clinical features (9). The prevalence of 
HBeAg-negative hepatitis as well as non-alcoholic 
fatty liver disease (NAFLD) has been increasing in the 
past decades (4,10). Increasing studies on chronic he-
patitis C with hepatic steatosis have been conducted, 
but little is known about CHB with steatosis. Hepatic 
steatosis may have different influences on the liver 
affected by other diseases. Therefore, it cannot always 
be considered as a “benign” condition and simply 
ignored. On the contrary, it has to be recognized as a 
“co-factor” capable of affecting the gravity and pro-
gression and also therapeutic perspectives of liver 
diseases.  
We compared the clinical and histological cha-
racteristics between HBeAg-negative CHB patients 
with and without steatosis, and the results demon-
strated significant increases in BMI, FBG, FINS, TG, 
TC, GGT, ALP, Glb and HOMA-IR in patients with 
steatosis, implying that obesity, diabetes and hyper-
lipemia appeared to be the risk factors in patients with 
steatosis, and insulin resistance might play an im-
portant role (12). HBeAg-negative CHB is characte-
rized by low spontaneous remission, frequent ALT 
flare, easy progression to cirrhosis, low HBV DNA 
titer and curative difficulty, and thus hepatic steatosis 
will definitely increase the difficulty of therapy in 
HBeAg-negative HB patients (13).  
In comparison to HBeAg-negative CHB with 
hepatic steatosis, the ALT, AST and HBV-DNA levels 
were higher in patients without steatosis, indicating 
that the ALT and AST flares may be associated with 
HBV DNA titer in our study, while in patients with 
hepatic steatosis, these parameters are more likely 
related to hepatic steatosis. Thus, for the treatment of 
HBeAg-negative CHB with hepatic steatosis, in addi-
tion to antivirus therapy and liver protection therapy, 
insulin resistance reduction, lipid modulation, diet 
restriction and exercise for prevention and control of 
risk factors are also important. Some HBeAg-negative 
CHB patients with hepatic steatosis may even 
progress into fibrosis and cirrhosis (14). In 
HBeAg-negative CHB patients with hepatic steatosis, 
the activity of hepatic inflammation may be associated 
w i t h  N A F L D  i n  t h e  p r e s e n c e  o f  s l i g h t l y  h i g h  A L T  
level and low HBV DNA level. Clinically, it is very 
difficult to conclude whether hepatitis is from steato-
sis and/or HBV infection through detecting ALT, 
HBeAg and HBV DNA levels (15). Under such condi-
tion, in addition to detection of the ALT, HBeAg and 
HBV DNA levels, BMI, FBG, FINS, TG, TC, GGT, 
ALP, Glb and HOMA-IR are also critical for diagnosis. 
If these parameters are abnormal, liver biopsy is 
strongly recommended in order to assess histology 
and prognosis. Our study demonstrated the signific-
ance of liver biopsy in determining the causes of high 
ALT levels. The most important limitation of this 
study is the lack of long-term follow-up and evalua-
tion of response to antiviral therapy in 
HBeAg-negative CHB patients with steatosis.  
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